首页>投融资
TFF Pharmaceuticals
增发
TFF Pharmaceuticals, Inc.于2018年1月24日在特拉华州注册成立。该公司是一家早期的生物制药公司,致力于基于其专利的薄膜冷冻(TFF)技术平台开发创新药物并将其商品化。该公司早期测试证实,他们的TFF平台可以显著提高水溶性差的药物的溶解度,水溶性差的药物约占全球主要药物的40%,从而改善了这些药物的药代动力学效应。
基本信息
-
公司全称TFF Pharmaceuticals Inc
-
类型肺部疾病治疗药物研发商
-
产业领域医药研发/制造
-
公司人数15~50人
-
地址1751 River Run Suite 400 Fort Worth Texas 76107
-
联系电话1-817-4386168
-
邮箱gmattes@tffpharma.com
-
成立时间2018-01-24
投融资
-
2024-03-22增发120万美元未透露
-
2023-08-17增发570万美元未透露
-
2023-06-26IPO后其他轮次297万美元National Institute of Allergy and Infectious Diseases
-
2023-05-01IPO后其他轮次未透露Leidos
-
2022-11-29增发1230万美元未透露
-
2020-08-11IPO后其他轮次2590万美元未透露
-
2020-08-11IPO后其他轮次2590万美元未透露
-
2019-10-25上市2035.0万美元未透露
-
2019-06-01A轮817万美元未透露
-
2019-06-01A轮817万美元未透露
-
2018-04-03A轮1400万美元Liquid Ventures
-
2018-04-03未公开1400万美元Liquid Venture Partners
- 加载更多
相关投融资企业
战略投资
Medic Life Sciences Inc是一家美国的生物技术公司,专注于开发创新的医疗设备和诊断技术。公司致力于改善患者的诊断和治疗体验,通过提供高效、便捷的医疗产品和服务,满足医疗市场的需求。其主要产品线包括医疗影像设备、诊断试剂和生物信息学工具等,通过不断的技术创新和市场拓展,为全球患者带来更好的医疗健康
收并购
Alderley Analytical is an independent Contract Research Organisation (CRO). We offer specialist bioanalytical services to support your drug development programmes, from discovery through to late stage clinical development, focusing on small molecules, large molecules, peptides, biologics and biomarkers.
Our biotech, pharma and CRO clients have discovered that keeping their bioanalysis with one provider means fewer laboratory transfers and no loss of bioanalytical knowledge of the molecule. By simplifying this process, it means less complications helping the rapid development of new drugs.
We take a flexible and responsive approach, using our collective expertise to develop novel bioanalytical methods and deliver your results on-time to the right quality. We also pride ourselves on excellent communication; you’ll find us easy to get hold of and we stay in touch, even if there’s no news to report.
As a GLP and GCP accredited laboratory, we can offer regulatory compliance where needed and are able to validate bioanalytical methods and deliver bioanalytical results to current FDA/EMA guidelines. Get in touch to discuss your bioanalysis requirements today.
Visit our website at www.alderleyanalytical.com for more information.
增发
Theriva Biologics, Inc.成立于1986年,是一家生物技术公司,专注于合成DNA为基础的疗法和治疗严重疾病的创新型疾病缓解药物的发展。该公司是一家多元化的临床阶段公司,开发旨在治疗高度未满足需求领域疾病的疗法。公司通过收购VCN Biosciences,SL进入肿瘤学领域,VCN Biosciences,SL开发了一种新的溶瘤腺病毒平台,设计用于静脉、玻璃体内和抗肿瘤递送以触发肿瘤细胞死亡,改善共同给药的癌症疗法对肿瘤的获取,并促进患者免疫系统产生强大而持续的抗肿瘤反应。